Adrenoleukodystrophy Clinical Trial
— MATRIXOfficial title:
MATRIX - "Modeling Macrophages Activation Pattern in X-linked Adrenoleukodystrophy, Metachromatic Leukodystrophy and Adult Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia"
NCT number | NCT04925349 |
Other study ID # | APHP190197 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | August 30, 2021 |
Est. completion date | February 2025 |
This study is a national, non-randomized, open-label, multi-site with minimal risk study in adult with adrenomyeloneuropathy (AMN), childhood and adult subjects with cerebral ALD (cALD), juvenile/adult metachromatic leukodystrophy (MLD) and adults with leukoencephalopathy and axonal spheroids and pigmented glia (ALSP). 49 subjects will be enrolled with one blood sample collection during one of their medical follow-up visit. This trial will evaluate the role of innate immunity to influence disease progression in X-ALD, MLD and ALSP, and if the mutations related to these leukodystrophies result in a specific immune response leading to the pathogenesis.
Status | Recruiting |
Enrollment | 56 |
Est. completion date | February 2025 |
Est. primary completion date | August 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 15 Months to 60 Years |
Eligibility | Inclusion Criteria: - Boys or girls aged between 15 months and 18 years (inclusive) diagnosed with MLD (low ARSA activity and accumulation of sulfatides in urine) - Boys aged between 3 and 18 years (inclusive) diagnosed with C-CALD (elevated levels of VLCFA and leukodystrophy at brain MRI) - Boys carrying ABCD1 mutations aged between 3 and 18 years (inclusive) (PRE-ALD) - Adult males or females aged between 18 and 60 diagnosed with MLD (low ARSA activity and accumulation of sulfatides in urine) - Adult males aged between 18 and 60 diagnosed with AMN (elevated VLCFA and clinical symptoms of AMN without leukodystrophy at brain MRI) - Adult male aged between 18 and 60 diagnosed with CALD (elevated VLCFA with leukodystrophy at brain MRI) - Adult male or female between 18 and 60 diagnosed with ALSP (CSF1R mutation and leukodystrophy at brain MRI) - Children (15 months-18 years) without neurologic disease (no obvious neurological symptoms, normal neurologic examination) - Informed consent obtained : - from the parents or guardian for children patients and children controls ; - from subject himself for adult patients. Exclusion Criteria: - Participation to a therapeutic clinical trial - Treatment likely to modify the immune system - Unable to have a blood collection (i.e. low hemoglobin level at the investigator's judgment) - Any other reason, to the discretion of the investigator - Children or adults without health insurance or social security |
Country | Name | City | State |
---|---|---|---|
France | AP-HP Hôpital Bicêtre | Le Kremlin-Bicêtre | |
France | AP-HP Hôpital La Pitié Salpêtrière | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Berger J, Forss-Petter S, Eichler FS. Pathophysiology of X-linked adrenoleukodystrophy. Biochimie. 2014 Mar;98(100):135-42. doi: 10.1016/j.biochi.2013.11.023. Epub 2013 Dec 4. — View Citation
Gieselmann V, Krageloh-Mann I. Metachromatic leukodystrophy--an update. Neuropediatrics. 2010 Feb;41(1):1-6. doi: 10.1055/s-0030-1253412. Epub 2010 Jun 22. — View Citation
Miron VE, Boyd A, Zhao JW, Yuen TJ, Ruckh JM, Shadrach JL, van Wijngaarden P, Wagers AJ, Williams A, Franklin RJM, Ffrench-Constant C. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat Neurosci. 2013 Sep;16(9):1211-1218. doi: 10.1038/nn.3469. Epub 2013 Jul 21. — View Citation
Weinhofer I, Zierfuss B, Hametner S, Wagner M, Popitsch N, Machacek C, Bartolini B, Zlabinger G, Ohradanova-Repic A, Stockinger H, Kohler W, Hoftberger R, Regelsberger G, Forss-Petter S, Lassmann H, Berger J. Impaired plasticity of macrophages in X-linked adrenoleukodystrophy. Brain. 2018 Aug 1;141(8):2329-2342. doi: 10.1093/brain/awy127. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Macrophages functionality - distribution of monocytes | distribution of monocytes in the CD14-/+/++ and CD16-/+ classification using flow cytometry (% of CD14++/16-; CD14++/16+; CD14+/16+; CD14-/16-) | 2 years after blood collection | |
Primary | Macrophages functionality - myelin phagocytosis capacity | percentage of myelin high, myelin low and myelin negative cells using flow cytometry | 2 years after blood collection | |
Primary | Macrophages functionality - HLA levels | maximum fluorescence intensity for HLA markers using flow cytometry | 2 years after blood collection | |
Secondary | Macrophages metabolic profiling | Macrophages metabolic profiling (>2000 metabolites) using liquid chromatography coupled to high resolution mass spectrometry | 2 years after blood collection | |
Secondary | Macrophages transcriptomic profiling | Macrophages transcriptomic profiling (>1200 coding and non coding genes) : RNA sequencing using NextSeq 500 Illumina (60 million single-end, 150 base reads ) and analysis (using FastQC, Picard-Tools, Samtools and rseqc softwares | 2 years after blood collection |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02254863 -
UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells
|
Phase 1 | |
Completed |
NCT00383448 -
HSCT for High Risk Inherited Inborn Errors
|
Phase 2 | |
Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
Completed |
NCT02961803 -
MD1003-AMN MD1003 in Adrenomyeloneuropathy
|
Phase 2/Phase 3 | |
Withdrawn |
NCT02948062 -
Early Diagnosis Of Childhood Cerebral ALD
|
||
Completed |
NCT02952482 -
Newborn Screening for Adrenoleukodystrophy
|
||
Recruiting |
NCT03789721 -
Adrenoleukodystrophy National Registry Study
|
||
Completed |
NCT04303416 -
Plasma Exchange With Albumin in AMN Patients
|
Phase 2/Phase 3 | |
Terminated |
NCT00545597 -
A Phase III Trial of Lorenzo's Oil in Adrenomyeloneuropathy
|
Phase 3 | |
Completed |
NCT03513328 -
Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02699190 -
LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
|
||
Recruiting |
NCT02559830 -
Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy
|
Phase 1/Phase 2 | |
Recruiting |
NCT00278044 -
Clinical Study and Gene Mutation Analysis of Adrenoleukodystrophy in Taiwanese Children
|
N/A | |
Completed |
NCT00176904 -
Stem Cell Transplant for Inborn Errors of Metabolism
|
Phase 2/Phase 3 | |
Completed |
NCT00007020 -
Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid
|
Phase 3 | |
Active, not recruiting |
NCT03231878 -
A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients.
|
Phase 2/Phase 3 | |
Recruiting |
NCT03047369 -
The Myelin Disorders Biorepository Project
|
||
Active, not recruiting |
NCT00005900 -
Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
|
N/A | |
Completed |
NCT00004450 -
Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy
|
N/A | |
Recruiting |
NCT04090268 -
Precision Exercise in Children With Malignant Hemopathies
|
N/A |